Obesity medicines coverage in U.S. Medicare Part D via a pilot programme, starting during 2026Introduction of lower prices for Novo Nordisk’s semaglutide medicines in U.S. Medicare Part D and Medicaid and in direct-to-patients cash channelNovo Nordisk currently expects an estimated negative low single-digit impact on global sales growth in 2026 Bagsværd, Denmark, 6 November 2025 – Today it was announced that Novo Nordisk has agreed with the U.S. Administration to lower drug prices beginning in 2026 and expa ...

Obesity medicines coverage in U.S. Medicare Part D via a pilot programme, starting during 2026Introduction of lower prices for Novo Nordisk’s semaglutide medicines in U.S. Medicare Part D and Medicaid and in direct-to-patients cash channelNovo Nordisk currently expects an estimated negative low single-digit impact on global sales growth in 2026 Bagsværd, Denmark, 6 November 2025 – Today it was announced that Novo Nordisk has agreed with the U.S. Administration to lower drug prices beginning in 2026 and expa ...